Fusion Antibodies (LSE:FAB) reported audited revenue of £2.1 million for the year ended 31 March 2026, while its operating loss narrowed to £1.13 million.
Underlying service revenue was £1.86 million, with the company reporting a 21% increase in service revenue during the second half compared with the first half. Gross margin for the year reached 53%.
The reduction in the operating loss came despite an increase in research and development expenditure. Fusion also recorded £872,000 of grant income during the period.
Fundraise Increases Year-End Cash
Fusion completed a fundraising of approximately £1.4 million in January 2026.
The company ended the financial year with cash of £1.04 million.
OptiMAL Platform Commercially Launched
During the year, Fusion commercially launched its OptiMAL antibody discovery platform in December 2025 following validation work with the US National Cancer Institute.
The company also progressed international patent protection for its Opti library technology in Japan, Canada and Australia.
Fusion said it is seeing engagement from larger organisations and is seeking business across additional areas, including veterinary applications.
Grant-Funded Antibody Programmes Progress
The company continued work on grant-funded research programmes, including its DR5 therapeutic antibody project.
Fusion Antibodies is a Belfast-based contract research organisation providing pre-clinical antibody discovery, engineering and supply services for therapeutic and diagnostic applications.
Its services include antibody generation, humanisation through its CDRx platform, stable cell-line production and antibody optimisation. The company serves pharmaceutical and biotechnology customers internationally.
Leave a Reply